Combined outcome of non‐fatal myocardial infarction, non‐fatal stroke, and total number of deaths · patients with acute coronary syndrome
Statins showed no clear difference in combined outcome of non‐fatal myocardial infarction, non‐fatal… compared with control at 4 months (3 to 6 months) (moderate certainty).
1 finding from 1 review
Death from all causes · patients with acute coronary syndrome
Statins showed no clear difference in death from all causes compared with control at 4 months (3 to 6 months) (moderate certainty).
1 finding from 1 review
Fatal & Nonfatal myocardial infarction or reinfarction · patients with acute coronary syndrome
Statins showed no clear difference in fatal and non‐fatal myocardial infarction or reinfarction compared with control at 4 months (3 to 6 months) (moderate certainty).
1 finding from 1 review
Fatal or nonfatal stroke · patients with acute coronary syndrome
Statins showed no clear difference in fatal and non‐fatal stroke compared with control at 4 months (3 to 6 months) (moderate certainty).
1 finding from 1 review
Unstable angina · patients with acute coronary syndrome
Statins probably leads to lower unstable angina compared with control at 4 months (3 to 6 months) (moderate certainty).
1 finding from 1 review
Acute Heart Failure · patients with acute coronary syndrome
Statins showed no clear difference in acute heart failure compared with control at 4 months (3 to 6 months) (moderate certainty).
1 finding from 1 review
Rhabdomyolysis · patients with acute coronary syndrome
Statins showed no clear difference in rhabdomyolysis compared with control at 4 months (3 to 6 months) (low certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in all‐cause mortality compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in myocardial infarction compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in any stroke compared with ezetimibe and statins (low certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes CVD compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes all‐cause mortality compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes myocardial infarction compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in CVD compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular mortality · people with hyperlipidaemia
1 finding from 1 review
Intervention not reported
Cardiovacular morbidity · people with hyperlipidaemia
1 finding from 1 review
Intervention not reported
At least 1 adverse event · people with hyperlipidaemia
The intervention showed no clear difference in at least 1 adverse event (low certainty).
1 finding from 1 review
Intervention not reported
Total Cholesterol (mg/dL) · people with hyperlipidaemia
1 finding from 1 review
Intervention not reported
LDL‐C (mg/dL) · people with hyperlipidaemia
1 finding from 1 review